Tag: CELG

Celgene Update (1-18-13)

OUTLOOK 2013, RAISING BUY LIMIT AND TARGET PRICE As recently as the summer of 2012, Celgene had a stable but slowing core business led by Revlimid but no apparent pipeline.  Questions arose about the company’s long-term growth. In a remarkable turn of events, the company and stock have been revived by not one but three[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Celgene Update (11-16-12)

Celgene’s stock is up since the last Issue on good news. The company announced that Abraxane has achieved overall survival (OS) is Phase III trial treating metastatic pancreatic cancer patients.  CELG did not provide any exact results as they plan to present the data at an upcoming scientific meeting. We do know that the company designed[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

Celgene Update (10-19-12)

Celgene’s stock is down since the last Issue as it also corrected this Friday. This week, additional information became available on the FDA’s website regarding the cancellation of the November 8th ODAC meeting originally scheduled to discuss pomalidomide. The website now specifically says that ”the issues for which the FDA was seeking the scientific input of the[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by